About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
Overview of Proteasome Inhibitors in MM: Bortezomib, Carfilzomib & Ixazomib
By
MyCancerHaven
FEATURING
Ravi Vij
,
Sikander Ailawadhi
By
MyCancerHaven
FEATURING
Ravi Vij
,
Sikander Ailawadhi
90 views
July 6, 2023
Click here to learn more about MyCancerHaven:
https://www.mycancerhaven.org/
0 Comments
Login to view comments.
Click here to Login
Featured Video
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
17:46
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …
Feat.
A. Jakubowiak
19:08
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…
Feat.
R. Banerjee
19:24
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…
Feat.
P. Richardson
17:52
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
Feat.
K. Anderson
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
06:19
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Dara-KRd in NDMM Without ASCT - Final Analy…
Feat.
B. Derman
05:35
Saurabh Chhabra
Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence
49:01
Scripps MD Anderson Cancer Center
Current Summary of the Multiple Myeloma Treatment Landscape
Feat.
R. Lu
26:46
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…
11:38
Heinz Ludwig
Maintenance Therapy in Myeloma: Which Agent and for How Long?
35:37
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
Feat.
D. Sherbenou
16:28
Total Health
Multiple Myeloma: A New Risk-Adapted Approach
Feat.
J. Chandler
03:42
Moffitt Cancer Center
New FDA Approvals of CAR-Ts Earlier in Myeloma: What You Need to Know
Feat.
D. Hansen
12:35
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…
Feat.
C. Cerchione
08:36
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Standard- and High-Risk ND Transplant-Eligi…
Feat.
N. Joseph
